Organon (OGN) Change in Receivables (2020 - 2026)
Organon (OGN) posted quarterly Change in Receivables of $111.0 million for Q2 2026, up 1333.33% year-over-year from $7.7 million in Q2 2025, and up 70.77% on a QoQ basis from $65.0 million in Q1 2026.
Organon (OGN) Change in Receivables (2020 - 2026) Analysis & Trends
Organon has reported Change in Receivables for 7 years, with the latest figure at $111.0 million in Q2 2026.
- Change in Receivables for Q2 2026 came in at $111.0 million, up 1333.33% year-over-year; the trailing twelve-month figure through Jun 2026 was $21.0 million (up 109.59% YoY), and the FY2025 annual result was -$79.0 million, up 79.37% from the prior year.
- Change in Receivables advanced to $111.0 million in Q2 2026, from $65.0 million in the prior quarter.
- Over five years, Change in Receivables peaked at $230.0 million in Q2 2023 and troughed at -$341.0 million in Q4 2024.
- A 5-year average of $2.7 million and a median of $4.5 million in 2022 frame the typical range for Change in Receivables.
- The widest annual swing landed in 2024, when Change in Receivables slumped 1362.96%; it then jumped 1333.33% in 2026.
- A 5-year view of Change in Receivables shows it stood at $4.0 million in 2022, then jumped by 575.0% to $27.0 million in 2023, then slumped by 1362.96% to -$341.0 million in 2024, then jumped by 53.08% to -$160.0 million in 2025, then surged by 169.38% to $111.0 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $111.0 million in Q2 2026, $65.0 million in Q1 2026, and -$160.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 111.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111.00 Mn |
| Jun 30, 2026 | 111.00 Mn |
| Mar 31, 2026 | 65.00 Mn |
| Mar 31, 2026 | 65.00 Mn |
| Dec 31, 2025 | -160.00 Mn |
| Dec 31, 2025 | -160.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | -9.00 Mn |
| Jun 30, 2025 | -9.00 Mn |
| Mar 31, 2025 | 85.00 Mn |
| Mar 31, 2025 | 85.00 Mn |
| Dec 31, 2024 | -341.00 Mn |
| Dec 31, 2024 | -341.00 Mn |
| Sep 30, 2024 | 46.00 Mn |
| Sep 30, 2024 | 46.00 Mn |
| Jun 30, 2024 | 75.00 Mn |
| Jun 30, 2024 | 75.00 Mn |
| Mar 31, 2024 | -163.00 Mn |
| Mar 31, 2024 | -163.00 Mn |